Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• Gilead Sciences (GILD) offers a forward dividend yield of approximately 2.5%, providing reliable quarterly income.
• The company has increased its dividend for 10 consecutive years, growing from $1.72 annually in 2015 to $3.28 today.
• Payout ratio stands at around 47%, indicating strong sustainability backed by earnings and free cash flow (FCF).
• Recent ex-dividend date was March 13, 2026, with a payment of $0.82 per share on March 30, 2026.
• Compared to biotech peers, GILD's yield is competitive among dividend payers, with superior cash flow coverage.
• Modest growth profile suits conservative income investors seeking stability over high yields.

Dividend Overview

Gilead Sciences (GILD), a leading biopharmaceutical company focused on HIV, oncology, and inflammatory diseases, maintains a consistent quarterly dividend policy. The forward annual dividend is $3.28 per share, yielding about 2.5% at current prices. Payments occur every three months, with the most recent payout of $0.82 per share following the ex-dividend date of March 13, 2026. This positions GILD as a modest dividend stock rather than a high-yield play, emphasizing reliability over aggressive payouts. While not a Dividend Aristocrat, its decade-long streak of increases appeals to investors prioritizing steady income in the volatile biotech sector.

Dividend History and Growth

Since initiating its dividend in 2015 at $1.72 annually, Gilead has demonstrated commitment to shareholder returns through consistent quarterly payments and annual hikes. The dividend has compounded at roughly 6.7% per year, reaching $3.28 forward in 2026. Recent increases include a step-up to $0.82 for Q1 2026 from prior $0.79 levels. No cuts have occurred, reflecting a long-term strategy supported by diversified revenue from blockbusters like Biktarvy and Trodelvy. This 10-year growth streak underscores GILD's evolution into a dividend growth contender in biotech.

Dividend Sustainability and Payout Ratio

GILD's dividend appears highly sustainable, with a payout ratio of approximately 47% of earnings, leaving ample room for reinvestment and growth. Earnings per share (EPS) trailing twelve months (TTM) cover the dividend over twice, while free cash flow (FCF) margins exceed 30%, providing robust coverage—far above the payout needs. Debt levels are manageable, with operating cash flow comfortably servicing obligations (over 40% coverage). Strong balance sheet and recurring revenues from chronic therapies further bolster confidence in ongoing payments amid R&D demands typical in pharma.

Dividend Compared to Industry Peers

In the biotech and pharma sector, GILD's 2.5% yield is solid but trails high-yield peers like Pfizer (PFE) at over 6.4% and AbbVie (ABBV) around 3.5-4%. Amgen (AMGN) offers a comparable 2.8-3.1% yield with a higher 67% payout ratio. Pure growth names like Vertex (VRTX) and Regeneron (REGN) pay no dividends, prioritizing R&D. GILD strikes a balance, offering income with better sustainability than ultra-high yielders burdened by elevated payouts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research.

Is This Stock Attractive for Dividend Investors?

Gilead Sciences (GILD) suits conservative dividend investors seeking modest yields with low risk of cuts, thanks to its sub-50% payout and potent FCF generation. Income-oriented portfolios may appreciate the quarterly cadence and 10-year growth history, providing compounding potential without excessive volatility exposure common in biotech. Long-term holders could benefit from steady increases amid pipeline advancements in HIV and oncology. However, those chasing double-digit yields might look elsewhere, as GILD's profile leans toward stability over aggressive income. Growth-dividend hybrids may find it appealing for balanced exposure, but sector headwinds like patent cliffs warrant monitoring. Overall, it fits patient investors prioritizing preservation and gradual appreciation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations